IN2014MN01056A - - Google Patents

Info

Publication number
IN2014MN01056A
IN2014MN01056A IN1056MUN2014A IN2014MN01056A IN 2014MN01056 A IN2014MN01056 A IN 2014MN01056A IN 1056MUN2014 A IN1056MUN2014 A IN 1056MUN2014A IN 2014MN01056 A IN2014MN01056 A IN 2014MN01056A
Authority
IN
India
Prior art keywords
antifactor
activity
less
heparin
malaria
Prior art date
Application number
Inventor
Hans Peter Ekre
Ulf Lindahl
Erik Holmer
Per Olov Eriksson
Anna Leitgeb
Mats Wahlgren
Stefania Tidia
Lino Liverani
Original Assignee
Dilaforette Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dilaforette Ab filed Critical Dilaforette Ab
Publication of IN2014MN01056A publication Critical patent/IN2014MN01056A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a chemically modified heparin with an antifactor II activity of less than 10 IU/mg an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use including treatment of malaria.
IN1056MUN2014 2011-12-19 2012-12-19 IN2014MN01056A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/SE2011/051538 WO2013095215A1 (en) 2011-12-19 2011-12-19 Low anticoagulant heparins
PCT/SE2012/051428 WO2013095276A1 (en) 2011-12-19 2012-12-19 Low anticoagulant heparins

Publications (1)

Publication Number Publication Date
IN2014MN01056A true IN2014MN01056A (en) 2015-05-01

Family

ID=48668926

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1056MUN2014 IN2014MN01056A (en) 2011-12-19 2012-12-19

Country Status (26)

Country Link
US (2) US9480701B2 (en)
EP (2) EP2794667B1 (en)
JP (2) JP6703806B2 (en)
CN (1) CN104053675B (en)
AU (1) AU2012354226B2 (en)
BR (1) BR112014014673B1 (en)
CA (2) CA2856477C (en)
CY (2) CY1120197T1 (en)
DK (2) DK2794667T3 (en)
ES (2) ES2669055T3 (en)
HR (2) HRP20180725T1 (en)
HU (2) HUE037554T2 (en)
IL (1) IL232903A (en)
IN (1) IN2014MN01056A (en)
MX (1) MX358439B (en)
MY (1) MY170069A (en)
NO (2) NO2794666T3 (en)
PH (1) PH12014501387B1 (en)
PL (2) PL2794666T3 (en)
PT (2) PT2794667T (en)
RS (2) RS57214B1 (en)
SI (2) SI2794666T1 (en)
SM (2) SMT201800218T1 (en)
TN (2) TN2014000237A1 (en)
WO (3) WO2013095215A1 (en)
ZA (1) ZA201403654B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2617764C2 (en) 2011-12-19 2017-04-26 Дилафор Аб Non-anticoagulant glycosaminoglycans with repeating disaccharide units, and their medical application
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
GB2515315A (en) 2013-06-19 2014-12-24 Dilafor Ab New Processes
EP2965764A1 (en) * 2014-07-11 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
US20170049862A1 (en) * 2014-04-30 2017-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for treating vaso-occlusive crisis
CN105504097B (en) * 2015-12-30 2018-07-03 深圳市海普瑞药业集团股份有限公司 A kind of sulfated heparin oligosaccharides and its preparation method and application
CN108424474B (en) * 2017-02-15 2023-07-25 清华大学 Deanticoagulated heparin derivatives and their use in the treatment of inflammatory bowel disease
EP3773770B1 (en) * 2018-04-13 2023-11-29 University of Virginia Patent Foundation Compositions and methods for preparing and using non-immunogenic fast annealing microporous annealed particle hydrogels
CN109481692A (en) * 2018-11-30 2019-03-19 东南大学 A kind of Artesunate heparin derivatives and its pharmaceutical composition and application
WO2023192344A1 (en) * 2022-03-29 2023-10-05 The Penn State Research Foundation Device and method for accelerating and guiding vascularization
US12444880B2 (en) 2022-05-05 2025-10-14 Tego Innovations, Inc. Magnetic power distribution assembly
CN119325383A (en) * 2022-06-06 2025-01-17 Ihp治疗公司 Chemically modified heparin
KR20250019674A (en) * 2022-06-06 2025-02-10 아이에이치피 테라퓨틱스 인크. chemically modified heparin
CN115448994B (en) * 2022-09-28 2023-08-01 山东大学 A kind of neutralizing anticoagulant low molecular weight heparin and its preparation method and application
US12059430B2 (en) 2022-09-29 2024-08-13 Adora Animal Health Corporation Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
GB2625581A (en) 2022-12-21 2024-06-26 Modus Therapeutics Ab New medical use
GB2627263A (en) * 2023-02-17 2024-08-21 Modus Therapeutics Ab New medical use
WO2024170746A1 (en) 2023-02-17 2024-08-22 Modus Therapeutics Ab New medical use of sevuparin in the treatment of endotoxemia
CN116854838A (en) * 2023-06-30 2023-10-10 重庆望业药物研究有限公司 Low molecular weight polysaccharides and their preparation methods and applications
GB202407366D0 (en) * 2024-05-23 2024-07-10 Glycos Biomedical Ltd Preparation of medium molecular weight heparin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2614026B1 (en) 1987-04-16 1992-04-17 Sanofi Sa LOW MOLECULAR WEIGHT HEPARINS WITH REGULAR STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS
EP0362810B1 (en) * 1988-10-07 1993-05-05 Hoechst Aktiengesellschaft Antimalarial compositions using quinidine, artemisinine and its derivatives
SE9002550D0 (en) 1990-08-01 1990-08-01 Kabivitrum Ab heparin fragments
SE9003181D0 (en) * 1990-10-04 1990-10-04 Kabivitrum Ab USE OF HEPARIN FRACTION
US5250519A (en) * 1991-03-29 1993-10-05 Glycomed Incorporated Non-anticoagulant heparin derivatives
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH0532703A (en) * 1991-07-26 1993-02-09 Terumo Corp Production of low-molecular weight heparin derivative
AU5442594A (en) 1992-10-13 1994-05-09 Virginia Commonwealth University Use of non-anticoagulant heparin for treating ischemia/reperfusion injury
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
EP0735050B1 (en) * 1995-03-31 2002-09-25 Hamilton Civic Hospitals Research Development, Inc. Compositions for inhibiting thrombogenesis
US5993810A (en) 1996-03-15 1999-11-30 Lebovitz; Shamir Israel Method of softening or ripening the cervix of a female mammal using collagenase
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
AU4572797A (en) 1996-10-15 1998-05-11 Toray Industries, Inc. Cervical canal maturing agent
GB9711443D0 (en) 1997-06-03 1997-07-30 Leo Pharm Prod Ltd Chemical suppositions
AU1173599A (en) * 1997-11-20 1999-06-15 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
US6596705B1 (en) 1998-02-09 2003-07-22 The Regents Of The University Of California Inhibition of L-selectin and P-selection mediated binding using heparin
DE69931038T2 (en) 1998-02-26 2006-11-23 Seikagaku Corp. NEW POLYSACCHARIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICAL COMPOSITIONS THEREOF CONTAINING THEM AS AN ACTIVE INGREDIENT
US6028061A (en) * 1998-06-18 2000-02-22 Children's Medical Center Corp Angiogenesis inhibitors and use thereof
US6492503B1 (en) * 1998-07-31 2002-12-10 Seikagaku Corporation Glycosaminoglycan and drug compositions containing the same
CZ20014665A3 (en) * 1999-06-30 2002-05-15 Hamilton Civic Hospitals Research Development, Inc Preparation containing heparin with average molecular weight
JP4897991B2 (en) * 1999-07-23 2012-03-14 ラボラトリオス ファルマセウティコス ロビ ソシエダッド アノニマ Ultra low molecular weight heparin composition
IT1316986B1 (en) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti GLYCOSAMINOGLICAN DERIVATIVES PARTIALLY DESULPHATED NONANTICOAGULANTS WITH ANTIANGIOGENIC ACTIVITY.
JP4585072B2 (en) * 2000-02-29 2010-11-24 扶桑薬品工業株式会社 Heparin depolymerization method, depolymerized heparin, derivatives thereof and pharmaceutical composition
ATE426805T1 (en) * 2000-09-12 2009-04-15 Massachusetts Inst Technology METHODS AND PRODUCTS ASSOCIATED WITH LOW MOLECULAR HEPARIN
SE521676C2 (en) 2002-01-02 2003-11-25 Dilafor Ab Use of glycosaminoglycans for the prevention and treatment of pain in full-term pregnancy
US20040072796A1 (en) 2002-04-18 2004-04-15 Embury Stephen H. Method and composition for preventing pain in sickle cell patients
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
EP1582531A1 (en) 2004-03-24 2005-10-05 Aventis Pharma S.A. Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
DK1758557T3 (en) * 2004-05-11 2011-10-24 Egalet Ltd Swellable dosage form comprising gellan gum
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
US7741311B2 (en) * 2005-01-03 2010-06-22 Shaker Mousa Composition and method for treating occlusive vascular diseases, nerve regeneration, and wound healing
MX2008000974A (en) * 2005-07-22 2008-03-27 Univ California Heparin compostions and selectin inhibition.
US20080214480A1 (en) * 2005-07-22 2008-09-04 Trf Pharma, Inc. Method for Treating Sickle Cell Disease and Sickle Cell Disease Sequalae
EP2447285A3 (en) * 2006-05-25 2013-01-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparin composition and uses thereof
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (en) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Polysaccharide compositions that are not anticoagulants
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
WO2009073184A1 (en) 2007-12-03 2009-06-11 Florida State University Research Foundation, Inc. Compositions for inducing labor and associated methods
AU2009231634B2 (en) * 2008-04-04 2014-05-15 University Of Utah Research Foundation Alkylated semi-synthetic glycosaminoglycosan ethers, and methods for making and using thereof
WO2010009492A1 (en) * 2008-07-25 2010-01-28 Alphapharm Pty Ltd ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 μM TO ABOUT 10 μM
US20120183976A1 (en) 2009-04-16 2012-07-19 He Zhou Methods of assessing activity of a polysaccharide composition
US20120108538A1 (en) * 2009-06-30 2012-05-03 James Beeson Sulfated polysaccharides having antiplasmodial activity and methods and products for identifying antiplasmodial activity
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
RU2617764C2 (en) 2011-12-19 2017-04-26 Дилафор Аб Non-anticoagulant glycosaminoglycans with repeating disaccharide units, and their medical application
MX2014011451A (en) 2012-03-26 2014-11-10 Dilafor Ab Method for treatment of labor arrest.
AU2013240597A1 (en) 2012-03-26 2014-10-16 Dilafor Ab Combination treatment comprising sulphated glycosaminoglycans for inducing labor

Also Published As

Publication number Publication date
RS57213B1 (en) 2018-07-31
SI2794667T1 (en) 2018-06-29
CA2856918C (en) 2017-07-04
EP2794666A4 (en) 2015-07-22
HUE037554T2 (en) 2018-09-28
TN2014000236A1 (en) 2015-09-30
DK2794666T3 (en) 2018-04-23
AU2012354226A1 (en) 2014-06-05
EP2794667A4 (en) 2015-07-22
EP2794666A1 (en) 2014-10-29
NO2794667T3 (en) 2018-07-21
HUE037555T2 (en) 2018-09-28
US20150031638A1 (en) 2015-01-29
MX358439B (en) 2018-08-21
SMT201800218T1 (en) 2018-05-02
BR112014014673A8 (en) 2017-07-04
MX2014006956A (en) 2014-10-17
NO2794666T3 (en) 2018-07-21
HRP20180726T1 (en) 2018-06-15
AU2012354226B2 (en) 2017-01-12
IL232903A0 (en) 2014-07-31
MY170069A (en) 2019-07-03
HK1199893A1 (en) 2015-07-24
WO2013095215A1 (en) 2013-06-27
SI2794666T1 (en) 2018-06-29
DK2794667T3 (en) 2018-04-23
ES2668273T3 (en) 2018-05-17
HRP20180725T1 (en) 2018-06-29
PH12014501387A1 (en) 2014-09-22
US9480701B2 (en) 2016-11-01
HK1200471A1 (en) 2015-08-07
US20140364369A1 (en) 2014-12-11
JP6703806B2 (en) 2020-06-03
BR112014014673B1 (en) 2021-02-17
BR112014014673A2 (en) 2017-06-13
SMT201800217T1 (en) 2018-05-02
CY1120197T1 (en) 2018-12-12
TN2014000237A1 (en) 2015-09-30
WO2013095276A1 (en) 2013-06-27
CN104053675B (en) 2016-10-12
CA2856918A1 (en) 2013-06-27
CA2856477A1 (en) 2013-06-27
PH12014501387B1 (en) 2014-09-22
PL2794666T3 (en) 2018-08-31
WO2013095277A1 (en) 2013-06-27
EP2794666B1 (en) 2018-02-21
ES2669055T3 (en) 2018-05-23
ZA201403654B (en) 2017-08-30
IL232903A (en) 2017-02-28
EP2794667A1 (en) 2014-10-29
CA2856477C (en) 2017-06-27
PT2794667T (en) 2018-05-16
NZ625096A (en) 2016-07-29
CY1120194T1 (en) 2018-12-12
JP2018154848A (en) 2018-10-04
PT2794666T (en) 2018-05-09
RS57214B1 (en) 2018-07-31
EP2794667B1 (en) 2018-02-21
JP2015500387A (en) 2015-01-05
US9480702B2 (en) 2016-11-01
CN104053675A (en) 2014-09-17
PL2794667T3 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
IN2014MN01056A (en)
DK2794665T3 (en) NON-ANTICOAGULATIVE GLYCOSAMINOGLYCANES COMPREHENSIVE DISACCHARID REPEATING UNIT AND MEDICAL USE THEREOF
IN2014DN09782A (en)
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
MY169328A (en) Compositions for the treatment of dry eye
EA201290497A1 (en) THERAPEUTIC POLYMERIC NANOPARTICLES, INCLUDING CORTICOSTEROIDS, AND METHODS OF OBTAINING SUCH
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
WO2013106385A3 (en) System and methods for determining tissue elasticity
MX2019005130A (en) Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
MX375019B (en) HYDROGEL MEMBRANE FOR ADHESION PREVENTION.
PH12013502149A1 (en) Modified acid alpha glucosidase with accelerated processing
MY151104A (en) Novel use
MX364220B (en) Methods of treating fibrosis.
NZ631279A (en) Method for treatment of labor arrest
NZ703260A (en) Polysaccharide compositions and methods of use
MX2014010940A (en) The use of antithrombin in the treatment of pre-eclampsia.
TN2012000581A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
PH12016501190B1 (en) Substituted piperidinyl-tetrahydroquinolines
MX2019009711A (en) Improvements in or relating to organic compounds.
TR201909158T4 (en) siRNA and its use in methods and compositions for the treatment and / or prevention of eye disorders.
FR2978665B1 (en) ANTISEPTIC COMPOSITION
MY174829A (en) Durable treatment with 4-aminopyridine in patients with demyelination
TR201908669T4 (en) Derivatives of N-desulfated glycosaminoglycans and their use as drugs.
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
MX371198B (en) VASOPROTECTIVE and CARDIOPROTECTIVE ANTIDIABETIC THERAPY.